Preliminary Programme

Preliminary pogramme of the “11th Berlin Conference on Life Sciences – Novel Antimicrobials and AMR Diagnostics”

Opening Session
8:45 Introduction
8:50 Welcome address
Gerd Geisslinger, Executive Institute Management
Fraunhofer Institute for Molecular Biology & Applied Ecology, GER
9:00

Setting the scene
Marc Gitzinger, CEO BioVersys AG, CH
and 
Vice-President, BEAM Alliance

Plenary Session
9:10

Keynotes

Overview of current development in the AMR field
Jean-Pierre Paccaud, Director of Business Development,
Global Antibiotics Research and Development Partnership (GARDP)

Antibiotic development: European strategy and pipeline
Mark Jones, Head of Project Management & Head of Microbiology,
Basilea Pharmaceutica Ltd, CH; Secretary, BEAM Alliance

Closing the gap - global strategies to bring therapies to the market,
Dame Sally Davies, Interagency Coordination Group on Antimicrobial Resistance, UN &
Chief Medical Officer, UK (requested)

AMR diagnostics: How to develop successful business cases?
Jorge Villacian, Chief Medical Officer, Janssen Diagnostics,
Pharmaceutical R&D, Johnson & Johnson, BE
Coffee break with posters & exhibition

Session 1
Market access in the era of AMR - from idea to product

Session 2
From basic research to market - recent academic anti-infective and diagnostics innovations
11:00 Introduction: How to protect IP in a field of multiple public, private and public/private collaborations? 
Ute Kilger, Partner, Boehmert & Boehmert, GER
11:00 Introduction: The value of academic research in AMR innovations
Herman Goossens, Head of LMM, Vaccine & Infectous Disease Institute, University of Antwerp, BE 
Handling innovative approaches from clinic to market & clinical trial design
  • Regulatory agency perspective Marco Cavaleri, European Medicines Agency (EMA) (requested)
  • SME perspective
    Glenn Dale, Head of Early Development, Polyphor Ltd, CH
Drug candidates for new strategies based on natural products
Rolf Müller, Managing Director, Helmholtz Institute for Pharmaceutical Research Saarland & Coordinator "Novel Antibiotics", German Center for Infection Research (DZIF), GER
Sustainable economic models to revitalise antibiotic development - lessons learned from DRIVE AB Christine Årdal, Senior Advisor, Norwegian Institute of Public Health, NO Biochip development for personalised medicine in infectious diseases/ Antimicrobial Resistance Diagnostics Challenge (AMR DxC)
Till Bachmann, Principal Investigator, University of Edinburgh, UK
The diagnostic perspective: the initiative FIND Catharina Boehme, CEO, Foundation for Innovative New Diagnostics (FIND) Diagnostic tools to distinguish between bacterial and viral infections to reduce antibiotic abuse
Per Venge, Professor, Uppsala University, SE
Panel discussion Challenges behind ideas and innovation: How to bring a candidate to the market?
12:40 Lunch break with posters & exhibition

Session 3
Technology highlights and challenges - novel antimicrobials

Session 4
Technology highlights and challenges – diagnostics
13:30 Introduction:

The value of SMEs in AMR innovations
Marie Petit, BEAM Alliance
13:30

Introduction:

Perspective of an European listed company
Achim Plum, CBO, Curetis AG, GER



Insights into the development of anti-infective therapies in AMR dedicated SMEs in Europe:

Presentations of six BEAM Alliance member companies 

The journey of MeMed towards a disruptive blood test that address antibiotic resistance Kfir Oved, CTO & Co-Founder, MeMed Diagnostics Ltd, ISR

Microscreen technology – a new MRSA test
Bruce Savage, CEO, GFC Diagnostics Ltd, UK

Further case studies of successful diagnostic developments in European SMEs

Panel discussion
The need for diversity to tackle AMR

Panel discussion
Regulation – a barrier for the introduction of new AMR diagnostics?
15:00 Coffee break with posters & exhibition
Closing session
Financing and funding opportunities for SMEs and start-ups in the AMR field
15:30 Interactive market place:

Investors & funders pitch & Q&A: e.g. AMRC, CARB-X, ENABLE, Forbion Capital Partners, GARDP, EIB

Investor talk: 
Which business models are worth to invest?

  • Holger Reithinger, Forbion Capital Partners, NL/GER 
  • Henri-François Boedt, European Investment Bank 
  • Kevin Outtersson, CARB-X, US 
  • Peter Jackson, ARMC, UK 
  • Anders Karlén, Leader of the managing entity at ENABLE, & Professor, Uppsala University, SE 

    Start-up pitch

    • Ajay Mistry, CEO & Co-Founder, Oppilotech, UK
    • Juan José Infante Viñolo, CEO & Co-Founder, Vaxdyn, ES
    • Andreas A. Bastian, CEO & Co-Founder, AGILeBiotics B.V., NL
    • Daniel Mark, CEO & Co-Founder, SPINDIAG GmbH, GER
    • Alexander Belcredi, CEO & Co-Founder, PhagoMed, AUT
    Start-up ceremony
    17:30Networking & reception